Chiang Kuei-Chen, Ohmori Naoya, Goto Takeshi
Kazusa Institute for Drug Discovery, Josai Internaional University, 2-1-6 Kazusa-Kamatari, Kisarazu, Chiba 292-0818, Japan.
Endocr Metab Immune Disord Drug Targets. 2011 Jun;11(2):173-80. doi: 10.2174/187153011795564197.
Organ transplantation has become a major therapeutic option for patients with irreversible organ diseases. Immunosuppressive agents are usually required to prevent allograft rejection in patients who undergo an organ transplantation. Such drugs suppress both specific and nonspecific immunity, and render the recipient more susceptible to both infection and malignancy. Therefore, the development of more effective and less toxic immunosuppressive agents could improve the clinical outcomes of organ transplant recipients. Since the early days of clinical and experimental liver transplantation, it has been known that the liver is less likely to be rejected in comparison to other organs and may be tolerogenic even across a fully allogeneic MHC barrier in some specific cases. Spontaneous acceptance of liver allografts has been observed in several species. Orthotopic liver transplantation (OLT) in certain rat strains is accepted without immunosuppressive agents and serum from post-OLT recipients displays immunosuppressive activity. Attempts have been made to identify the immunosuppressive factors that are present in post-OLT serum to elucidate the mechanism of immunological tolerance and to discover novel immunosuppressive agents for potential use in organ transplantation. In this review we will focus on established and recent findings in the identification of immunosuppressive factors in a rat tolerogenic OLT model. The most recent therapeutic methods in organ transplantation and future prospects will be discussed.
器官移植已成为患有不可逆器官疾病患者的主要治疗选择。对于接受器官移植的患者,通常需要使用免疫抑制剂来防止同种异体移植排斥反应。这类药物会抑制特异性免疫和非特异性免疫,使接受者更容易受到感染和患恶性肿瘤。因此,开发更有效且毒性更小的免疫抑制剂可以改善器官移植受者的临床结局。自临床和实验性肝移植早期以来,人们就知道与其他器官相比,肝脏被排斥的可能性较小,并且在某些特定情况下,即使跨越完全异基因的主要组织相容性复合体(MHC)屏障,肝脏也可能具有免疫耐受性。在几个物种中都观察到了肝脏同种异体移植的自发接受情况。某些大鼠品系的原位肝移植(OLT)在不使用免疫抑制剂的情况下即可被接受,并且OLT术后受者的血清具有免疫抑制活性。人们已尝试鉴定OLT术后血清中存在的免疫抑制因子,以阐明免疫耐受机制,并发现可用于器官移植的新型免疫抑制剂。在这篇综述中,我们将重点关注大鼠免疫耐受OLT模型中免疫抑制因子鉴定方面已有的和最新的研究结果。还将讨论器官移植中最新的治疗方法和未来前景。